Compare
PTC Therapeutics, Inc. vs Phibro Animal Health Corp vs Alkermes plc. vs Sarepta Therapeutics, Inc.
| Latest fiscal year | PTC Therapeutics, Inc. PTCT | Phibro Animal Health Corp PAHC | Alkermes plc. ALKS | Sarepta Therapeutics, Inc. SRPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.73B | $1.52B | $1.48B | $2.20B |
| Revenue growth (YoY) | +114.5% | +17.1% | -5.2% | +15.6% |
| Gross margin | n/a | 33.8% | 86.7% (computed) | n/a |
| Operating margin | 50.1% | 12.8% | 17.2% | -31.8% |
| Net margin | 39.4% | 6.6% | 16.4% | -32.5% |
| Net income | $682.64M | $99.72M | $241.66M | -$713.41M |
| EPS (Diluted) | $7.78 | $2.43 | $1.43 | -$7.13 |
| Operating cash flow | $711.20M | $68.95M | $520.75M | -$205.48M |
| Free cash flow | $702.34M | $9.87M | $480.33M | -$307.45M |
| Cash & equivalents | $984.65M | $61.42M | $388.57M | $801.28M |
| Total assets | $2.90B | $1.50B | $2.49B | $3.35B |
| Total liabilities | $3.10B | $1.12B | $667.70M | $2.21B |
| Shareholders' equity | -$205.31M | $385.48M | $1.82B | $1.14B |
| Return on year-end equity | n/a | 25.9% | 13.3% | -62.5% |
| Shares outstanding | 81.47M | n/a | 165.61M | 104.96M |
Revenue, most recent five fiscal years
| Fiscal year | PTC Therapeutics, Inc. | Phibro Animal Health Corp | Alkermes plc. | Sarepta Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.73B Ended 2025-12-31 | $1.52B Ended 2026-06-30 | $1.48B Ended 2025-12-31 | $2.20B Ended 2025-12-31 |
| 1 year earlier | $806.78M Ended 2024-12-31 | $1.30B Ended 2025-06-30 | $1.56B Ended 2024-12-31 | $1.90B Ended 2024-12-31 |
| 2 years earlier | $937.82M Ended 2023-12-31 | $1.02B Ended 2024-06-30 | $1.66B Ended 2023-12-31 | $1.24B Ended 2023-12-31 |
| 3 years earlier | $698.80M Ended 2022-12-31 | $977.89M Ended 2023-06-30 | $1.11B Ended 2022-12-31 | $933.01M Ended 2022-12-31 |
| 4 years earlier | $538.59M Ended 2021-12-31 | $942.26M Ended 2022-06-30 | $1.17B Ended 2021-12-31 | $701.89M Ended 2021-12-31 |